Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II
- 1 June 2000
- journal article
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 14 (3), 249-252
- https://doi.org/10.1016/s1053-0770(00)90118-6
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- ON-LINE MONITORING OF ECARIN CLOTTING TIME DURING CPB WITH HIRUDIN DUE TO HIT IIAnesthesia & Analgesia, 1998
- Novel anticoagulants based on direct inhibition of thrombin and factor XaCoronary Artery Disease, 1998
- Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Type IISeminars in Thrombosis and Hemostasis, 1997
- Quantitative Determination of Hirudin in Blood and Body FluidsSeminars in Thrombosis and Hemostasis, 1996
- Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopeniaThrombosis Research, 1996
- Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable anginaJournal of the American College of Cardiology, 1995
- Use of recombinant hirudin as antithrombotic treatment in patients with heparin‐induced thrombocytopeniaAmerican Journal of Hematology, 1995
- Recombinant hirudin (HBW 023): Biological data of ten patients with severe venous thrombo‐embolismAmerican Journal of Hematology, 1995
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990